Research Progress in the Treatment of Pituitary Tumors

  • Wengan Ji Department of Changzhi Medical College
  • Ruixue Xie Department of Changzhi Medical College
  • Shaoze Qin Department of Changzhi Medical College
  • Long Wang Department of Changzhi Medical College
  • Wenlong Tang Department of Changzhi Medical College
Keywords: Pituitary Tumor, Treatment, Research Progress

Abstract

Pituitary tumor is a common intracranial neuroendocrine tumor, generally belonging to benign tumors. It mainly originates from pituitary cells in the sella region. There is no significant difference in the ratio of men to women. The tumor grows to the lower part of the parasellar thalamus, and may even reach the third ventricle to involve the cavernous sinus, extend into the middle cranial fossa, grow into the interpeduncular cistern, and enter the nasopharynx in the sphenoid sinus. A few tumors are rich in blood supply and easy to bleed, leading to pituitary tumor stroke. The incidence of pituitary tumor ranks the third among intracranial tumors. In recent years, with the development of endocrine examination and imaging technology, the detection rate is increasing year by year. The hormone disorder and the pressure on the surrounding important tissues will have a great impact on the quality of life of patients, and have a great impact on the growth and development of patients, labor ability, growth and development and social psychology. In this paper, the research progress of three methods for the treatment of pituitary tumor (surgical therapy, drug therapy, radiation therapy) is reviewed, aiming to provide reference for the clinical treatment of this disease.

References

[1] Karimian-Jazi K. [Pituitary gland tumors]. Radiologe. 2019 ;59(11):982-991.

[2] Zhang Q, Wang Y, Zhou Y, et al. Potential biomarkers of miRNA in non-functional pituitary adenomas. World J Surg Oncol. 2021;19(1):270.

[3] Molitch M E. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017; 317(5):516-524.

[4] Kalogeridi MA, Kougioumtzopoulou A, Zygogianni A, et al. Stereotactic radiosurgery and radiotherapy for acoustic neuromas. Neurosurg Rev. 2020; 43(3): 941-949.

[5] Gupta T, Chatterjee A. Modern Radiation Therapy for Pituitary Adenoma: Review of Techniques and Outcomes. Neurol India. 2020;68(Supplement):113-122.

[6] Zou Y, Li D, Gu J, et al. The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. BMC Endocr Disord. 2021; 21(1):225.

[7] Petersenn S, Giustina A. Diagnosis and management of prolactinomas: current challenges. Pituitary. 2020;23(1):1-2.

[8] Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331(14):904-909.

[9] Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008;37(1):67-99.

[10] Fleseriu M, Biller BM, Findling JW, et al. Seismic Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012; 97(6): 2039-2049.

[11] Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology. Eur J Endocrinol. 2018;178(1):1-24.
Published
2023-06-01
Section
Original Research Article